Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Absolute Bioavailability of Xevinapant in Healthy Males
NCT04962724Phase 1Completed
- Sponsor
- Debiopharm
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xevinapant in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Debiopharm. Primary endpoints: Mass Balance Recovery Measured Through Total Radioactivity Excreted in Expired Air, Urine and Feces, Area Under Concentration-Time Curve (AUC0-infinity, AUC0-24, AUC0-last) and 8 more. Started Aug 2021; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04962724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962724.